Expand DTIL Menu
DTIL MENU

DTIL Latest Press Releases

-- May 1, 2024 --

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 Business Wire 7:05 AM

-- April 16, 2024 --

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics Business Wire 4:15 PM

-- April 4, 2024 --

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. Business Wire 11:00 AM

-- March 27, 2024 --

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update Business Wire 6:45 AM

-- March 20, 2024 --

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 Business Wire 4:30 PM

-- March 19, 2024 --

Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy Business Wire 7:00 AM

-- March 6, 2024 --

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency Business Wire 8:45 AM
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506 Business Wire 8:00 AM

-- March 1, 2024 --

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants Business Wire 6:30 AM

-- February 29, 2024 --

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants Business Wire 4:01 PM

-- February 20, 2024 --

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences Business Wire 7:00 AM

-- February 14, 2024 --

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness Business Wire 7:00 AM

-- February 13, 2024 --

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations Business Wire 7:00 AM

-- February 12, 2024 --

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases Business Wire 7:00 AM

-- February 9, 2024 --

Precision BioSciences to Effect a Reverse Stock Split Business Wire 7:00 AM

-- January 9, 2024 --

Biotech Bid Up Before Opening Bell Yolowire 9:59 AM
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases Business Wire 7:00 AM

-- December 13, 2023 --

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE Business Wire 8:20 AM
iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506 Business Wire 8:00 AM

-- December 4, 2023 --

Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases Business Wire 7:00 AM